Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 17/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311383 | 1.00 | CCR3 (0.63) | CCR3HTR2AHTT | |
| SCHEMBL6305758 | 0.92 | CCR3 (0.53) | CCR3HTR2A | |
| SCHEMBL6305756 | 0.92 | CCR3 (0.53) | CCR3HTR2A | |
| SCHEMBL6303817 | 0.91 | CCR3 (0.53) | CCR3HTR2A | |
| SCHEMBL6303815 | 0.91 | CCR3 (0.53) | CCR3HTR2A | |
| SCHEMBL6303706 | 0.89 | FPR1 (0.58) | CCR3HTT | |
| SCHEMBL6303707 | 0.89 | FPR1 (0.58) | CCR3HTT | |
| SCHEMBL6312016 | 0.89 | CCR3 (0.56) | CCR3HTT | |
| SCHEMBL6312019 | 0.89 | CCR3 (0.56) | CCR3HTT | |
| SCHEMBL6303748 | 0.88 | FAAH (0.52) | CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1453825-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
| WO-2003045937-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | CCR3 2/4885HTR2A 1107/4885HTT 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.